Sex differences in the GSK3Β-mediated survival of adherent leukemic progenitors

Oncogene

Volumn 31, Issue 6, 2012, Pages 694-705

  Bertrand, J ^a   Despeaux, M ^a   Joly, S ^b   Bourogaa, E ^a   Gallay, N ^a   Demur, C ^c,d   Bonnevialle, P ^d   Louache, F ^e   Maguer Satta, V ^b   Vergnolle, N ^a   Payrastre, B ^d,f   Racaud Sultan, C ^a  

^a University of Toulouse III   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Université de Toulouse   (France)

Author keywords

cell adhesion; cell survival; GSK3b; leukemia

Indexed keywords

CD34 ANTIGEN; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTEGRIN; PHOSPHOPROTEIN PHOSPHATASE 2A; RECEPTOR FOR ACTIVATED C KINASE 1; SERINE; VERY LATE ACTIVATION ANTIGEN 5;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL ADHESION; CELL SURVIVAL; CLINICAL ARTICLE; CLONOGENESIS; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA STEM CELL; LEUKEMOGENESIS; MALE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SEX DIFFERENCE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL ADHESION; CELL SURVIVAL; CELLS, CULTURED; ETOPOSIDE; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GTP-BINDING PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLES; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA; MALE; MALEIMIDES; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTEIN PHOSPHATASE 2; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; SEX FACTORS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84856961657     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.258     Document Type: Article

References (38)

1. Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. (2006). TLR7 ligands induce higher IFN-alpha production in females. J Immunol 177: 2088-2096. (Pubitemid 44200966)
2. Bhatia R, McCarthy JB, Verfaillie CM. (1996). Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87: 3883-3891. (Pubitemid 26129618)
3. Del Vecchio I, Zuccotti A, Pisano F, Canneva F, Lenzken SC, Rousset F et al. (2009). Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein. Gene 430: 17-29.
4. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F et al. (2006). A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113-3122. (Pubitemid 43881553)
5. De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert L, Payrastre B et al. (2010). A new a5b1 integrin-dependent survival pathway through GSK3b activation in leukemic cells. PloS ONE 5: e9807.
6. De Vries JF, Falkenburg JH, Willemze R, Barge RM. (2006). The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 91: 912-919. (Pubitemid 44023144)
7. Despeaux M, Labat E, Gadelorge M, Prade N, Bertrand J, Demur C et al. (2011). Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia (advance online publication 7 June 2011; doi:10.1038/leu.2011.145).
8. Dick JE, Lapidot T. (2005). Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 82: 389-396. (Pubitemid 46638686)
9. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. (2007). Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27: 4006-4017. (Pubitemid 47010998)
10. Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC et al. (2004). Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 279: 38563-38570. (Pubitemid 39296010)
11. Edderkaoui M, Hong P, Lee JK, Pandol SJ, Gukovskaya AS. (2007. Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin. J Biol Chem 282: 26646-26655. (Pubitemid 47501963)
12. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS et al. (2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169. (Pubitemid 40720758)
13. Holmes T, O'Brien TA, Knight R, Lindeman R, Shen S, Song E et al. (2008). Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 26: 1288-1297.
14. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321. (Pubitemid 350076512)
15. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kähäri VM, Heino J. (2002). Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol 22: 1352-1359. (Pubitemid 34150772)
16. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174. (Pubitemid 44527352)
17. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L et al. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31-42.
18. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.
19. Kiely PA, Baillie GS, Lynch MJ, Houslay MD, O'Connor R. (2008). Tyrosine 302 in RACK1 is essential for insulin-like growth factor-Imediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. J Biol Chem 283: 22952-22961.
20. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M et al. (2009). Functional proteomic profiling of AML predicts response and survival. Blood 113: 154-164.
21. Kubota T, Yokosawa N, Yokota S, Fujii N. (2002). Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J Virol 76: 12676-12682. (Pubitemid 35386952)
22. Li ZW, Dalton WS. (2006). Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20: 333-342. (Pubitemid 44691998)
23. Luo J. (2009). Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194-200.
24. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. (2003). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158-1165. (Pubitemid 37173700)
25. Mayack SR, Shadrach JL, Kim FS, Wagers AJ. (2010). Systemic signals regulate ageing and rejuvenation of blood stem cell niches. Nature 463: 495-500.
26. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. (2007). Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110: 735-742. (Pubitemid 47105412)
27. Papasozomenos SCh, Shanavas A. (2002). Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 99: 1140-1145. (Pubitemid 34136460)
28. Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P et al. (2004). Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64: 3191-3197. (Pubitemid 38581422)
29. Sampaio AL, Zahn G, Leoni G, Vossmeyer D, Christner C, Marshall JF et al. (2010). Inflammation-dependent \{alpha\}5\{beta\}1 (very late antigen-5) expression on leukocytes reveals a functional role for this. J Leukoc Biol 87: 877-884.
30. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A et al. (2010). Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28: 275-280.
31. Schiller G, Gajewski J, Lee M, Ho W, Territo M, Champlin R. (1994). Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Leuk Lymphoma 15: 85-90. (Pubitemid 24303384)
32. Sun M, Song L, Li Y, Zhou T, Jope RS. (2008). Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ 15: 1887-1900.
33. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. (2006). Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 12: 89-98. (Pubitemid 43050082)
34. Vialle-Castellano A, Gaugler B, Mohty M, Isnardon D, van Baren N, Olive D. (2004). Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 18: 426-433. (Pubitemid 38425855)
35. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH et al. (2010). GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17: 597-608.
36. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. (2008). Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455: 1205-1209.
37. Xu Q, Thompson JE, Carroll M. (2005). mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106: 4261-4268. (Pubitemid 41775935)
38. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB et al. (2006). Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20: 1211-1216. (Pubitemid 43905823)